Sarah Zohar

List of Publications by Year in Descending Order

102 papers	2,502 citations	27 h-index	47 g-index
109 ext. papers	2,979 ext. citations	3.7 avg, IF	4.78 L-index

#	Paper	IF	Citations
102	Bayesian modeling of a bivariate toxicity outcome for early phase oncology trials evaluating dose regimens. *Statistics in Medicine*, **2021**, 40, 5096-5114	2.3	1
101	Competing Risks Model with Short-Term and Long-Term Covariate Effects for Cancer Studies. *Statistics in Biosciences*, **2021**, 13, 142-159	1.5	
100	Bayesian dose regimen assessment in early phase oncology incorporating pharmacokinetics and pharmacodynamics. *Biometrics*, **2021**,	1.8	2
99	An adaptive power prior for sequential clinical trials - Application to bridging studies. *Statistical Methods in Medical Research*, **2020**, 29, 2282-2294	2.3	11
98	Efficient Adaptive Designs for Clinical Trials of Interventions for COVID-19. *Statistics in Biopharmaceutical Research*, **2020**, 12, 483-497	1.2	22
97	Embedding a COVID-19 group sequential clinical trial within an ongoing trial: lessons from an unusual experience. *Statistics in Biopharmaceutical Research*, **2020**, 12, 478-482	1.2	5
96	Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19: A Randomized Clinical Trial. *JAMA - Journal of the American Medical Association*, **2020**, 324, 1298-1306	27.4	229
95	Clinical Trials Impacted by the COVID-19 Pandemic: Adaptive Designs to the Rescue?. *Statistics in Biopharmaceutical Research*, **2020**, 12, 461-477	1.2	19
94	Integration of elicited expert information via a power prior in Bayesian variable selection: Application to colon cancer data. *Statistical Methods in Medical Research*, **2020**, 29, 541-567	2.3	2
93	A Bayesian non-inferiority approach using experts$P$margin elicitation - application to the monitoring of safety events. *BMC Medical Research Methodology*, **2019**, 19, 187	4.7	2
92	Dose-finding designs for cumulative toxicities using multiple constraints. *Biostatistics*, **2019**, 20, 17-29	3.7	8
91	Bayesian variable selection based on clinical relevance weights in small sample studies-Application to colon cancer. *Statistics in Medicine*, **2019**, 38, 2228-2247	2.3	5
90	Levetiracetam optimal dose-finding as first-line treatment for neonatal seizures occurring in the context of hypoxic-ischaemic encephalopathy (LEVNEONAT-1): study protocol of a phase II trial. *BMJ Open*, **2019**, 9, e022739	3	11
89	Recommendations for the design of therapeutic trials for neonatal seizures. *Pediatric Research*, **2019**, 85, 943-954	3.2	28
88	A dose finding design for seizure reduction in neonates. *Journal of the Royal Statistical Society Series C: Applied Statistics*, **2019**, 68, 427-444	1.5	1
87	Bayesian sample size determination for phase IIA clinical trials using historical data and semi-parametric priorβ elicitation. *Pharmaceutical Statistics*, **2019**, 18, 198-211	1	1
86	Bayesian treatment comparison using parametric mixture priors computed from elicited histograms. *Statistical Methods in Medical Research*, **2019**, 28, 404-418	2.3	7

85	dfpk: An R-package for Bayesian dose-finding designs using pharmacokinetics (PK) for phase I clinical trials. *Computer Methods and Programs in Biomedicine*, **2018**, 157, 163-177	6.9	6
84	Approaches to sample size calculation for clinical trials in rare diseases. *Pharmaceutical Statistics*, **2018**, 17, 214-230	1	11
83	Phase I/II dose-finding design for molecularly targeted agent: Plateau determination using adaptive randomization. *Statistical Methods in Medical Research*, **2018**, 27, 466-479	2.3	17
82	Unified approach for extrapolation and bridging of adult information in early-phase dose-finding paediatric studies. *Statistical Methods in Medical Research*, **2018**, 27, 1860-1877	2.3	13
81	Value of information methods to design a clinical trial in a small population to optimise a health economic utility function. *BMC Medical Research Methodology*, **2018**, 18, 20	4.7	8
80	Recent advances in methodology for clinical trials in small populations: the InSPiRe project. *Orphanet Journal of Rare Diseases*, **2018**, 13, 186	4.2	22
79	Exploring how non-inferiority and equivalence are assessed in paediatrics: a systematic review. *Archives of Disease in Childhood*, **2018**, 103, 1067-1075	2.2	1
78	Dose-finding methods for Phase I clinical trials using pharmacokinetics in small populations. *Biometrical Journal*, **2017**, 59, 804-825	1.5	25
77	Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: Results from the ANTHALYA trial. *European Journal of Cancer*, **2017**, 70, 133-142	7.5	52
76	Does the low prevalence affect the sample size of interventional clinical trials of rare diseases? An analysis of data from the aggregate analysis of clinicaltrials.gov. *Orphanet Journal of Rare Diseases*, **2017**, 12, 44	4.2	19
75	Determination of the optimal sample size for a clinical trial accounting for the population size. *Biometrical Journal*, **2017**, 59, 609-625	1.5	23
74	Comments on ‘A comparative study of adaptive dose-finding designs for phase I oncology trials of combination therapies’. *Statistics in Medicine*, **2016**, 35, 475-8	2.3	
73	Systematic reviews in paediatric multiple sclerosis and Creutzfeldt-Jakob disease exemplify shortcomings in methods used to evaluate therapies in rare conditions. *Orphanet Journal of Rare Diseases*, **2016**, 11, 16	4.2	8
72	Evaluation of the Effects of Pasireotide LAR Administration on Lymphocele Prevention after Axillary Node Dissection for Breast Cancer: Results of a Randomized Non-Comparative Phase 2 Study. *PLoS ONE*, **2016**, 11, e0156096	3.7	2
71	A Bayesian Hybrid Adaptive Randomisation Design for Clinical Trials with Survival Outcomes. *Methods of Information in Medicine*, **2016**, 55, 4-13	1.5	2
70	Dose-Finding Study of Omeprazole on Gastric pH in Neonates with Gastro-Esophageal Acid Reflux Using a Bayesian Sequential Approach. *PLoS ONE*, **2016**, 11, e0166207	3.7	5
69	dfcomb: An R-package for phase I/II trials of drug combinations. *Computer Methods and Programs in Biomedicine*, **2016**, 125, 117-33	6.9	1
68	Decision-theoretic designs for small trials and pilot studies: A review. *Statistical Methods in Medical Research*, **2016**, 25, 1022-38	2.3	15

67	Bumetanide for the treatment of seizures in newborn babies with hypoxic ischaemic encephalopathy (NEMO): an open-label, dose finding, and feasibility phase 1/2 trial. *Lancet Neurology, The*, **2015**, 14, 469-77	24.1	170
66	Designs of drug-combination phase I trials in oncology: a systematic review of the literature. *Annals of Oncology*, **2015**, 26, 669-674	10.3	39
65	Bumetanide for neonatal seizures-back from the cotside. *Nature Reviews Neurology*, **2015**, 11, 724	15	14
64	Designing a Pediatric Study for an Antimalarial Drug by Using Information from Adults. *Antimicrobial Agents and Chemotherapy*, **2015**, 60, 1481-91	5.9	5
63	An extension of Bayesian predictive sample size selection designs for monitoring efficacy and safety. *Statistics in Medicine*, **2015**, 34, 3029-39	2.3	6
62	A Bayesian dose finding design for clinical trials combining a cytotoxic agent with a molecularly targeted agent. *Journal of the Royal Statistical Society Series C: Applied Statistics*, **2015**, 64, 215-229	1.5	24
61	Response to comments on Competing designs for drug combination in phase I dose-finding clinical trials by G. Yin, R. Lin and N. Wages. *Statistics in Medicine*, **2015**, 34, 23-6	2.3	1
60	Competing designs for drug combination in phase I dose-finding clinical trials. *Statistics in Medicine*, **2015**, 34, 1-12	2.3	29
59	Optimizing Sedative Dose in Preterm Infants Undergoing Treatment for Respiratory Distress Syndrome. *Journal of the American Statistical Association*, **2014**, 109, 931-943	2.8	19
58	Phase I/II Clinical Trials **2014**, 658-666		
57	A Bayesian dose-finding design for drug combination clinical trials based on the logistic model. *Pharmaceutical Statistics*, **2014**, 13, 247-57	1	41
56	An adaptive model switching approach for phase I dose-finding trials. *Pharmaceutical Statistics*, **2013**, 12, 225-32	1	
55	Dose-finding designs using a novel quasi-continuous endpoint for multiple toxicities. *Statistics in Medicine*, **2013**, 32, 2728-46	2.3	31
54	Modeling of experts divergent prior beliefs for a sequential phase III clinical trial. *Clinical Trials*, **2013**, 10, 505-14	2.2	9
53	What is the ED95 of prilocaine for femoral nerve block using ultrasound?. *British Journal of Anaesthesia*, **2013**, 110, 831-6	5.4	4
52	Using the continual reassessment method to estimate the minimum effective dose in phase II dose-finding studies: a case study. *Clinical Trials*, **2013**, 10, 414-21	2.2	17
51	Application of the continual reassessment method to dose-finding studies in regional anesthesia: an estimate of the ED95 dose for 0.5% bupivacaine for ultrasound-guided supraclavicular block. *Anesthesiology*, **2013**, 119, 29-35	4.3	14
50	Similar outcomes after primary and secondary esophagocoloplasty for caustic injuries. *Annals of Thoracic Surgery*, **2012**, 93, 905-12	2.7	10

49	A Bayesian predictive sample size selection design for single-arm exploratory clinical trials. *Statistics in Medicine*, **2012**, 31, 4243-54	2.3	9
48	The impact of non-drug-related toxicities on the estimation of the maximum tolerated dose in phase I trials. *Clinical Cancer Research*, **2012**, 18, 5179-87	12.9	18
47	Surgery for caustic injuries of the upper gastrointestinal tract. *Annals of Surgery*, **2012**, 256, 994-1001	7.8	50
46	Anal carcinoma in HIV-infected patients in the era of antiretroviral therapy: a comparative study. *Diseases of the Colon and Rectum*, **2011**, 54, 729-35	3.1	29
45	Posterior maximization and averaging for Bayesian working model choice in the continual reassessment method. *Statistics in Medicine*, **2011**, 30, 1563-73	2.3	13
44	An approach to meta-analysis of dose-finding studies. *Statistics in Medicine*, **2011**, 30, 2109-16	2.3	9
43	Dose-finding approach for dose escalation with overdose control considering incomplete observations. *Statistics in Medicine*, **2011**, 30, 1584-94	2.3	34
42	Planning a Bayesian early-phase phase I/II study for human vaccines in HER2 carcinomas. *Pharmaceutical Statistics*, **2011**, 10, 218-26	1	10
41	Incorporating lower grade toxicity information into dose finding designs. *Clinical Trials*, **2011**, 8, 370-9	2.2	28
40	Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study. *Neuro-Oncology*, **2010**, 12, 401-8	1	147
39	Retrospective robustness of the continual reassessment method. *Journal of Biopharmaceutical Statistics*, **2010**, 20, 1013-25	1.3	24
38	Late morbidity after colon interposition for corrosive esophageal injury: risk factors, management, and outcome. A 20-years experience. *Annals of Surgery*, **2010**, 252, 271-80	7.8	62
37	Esophageal replacement by allogenic aorta in a porcine model. *Surgery*, **2010**, 148, 39-47	3.6	33
36	Primary hyperparathyroidism from parathyroid microadenoma: specific features and implications for a surgical strategy in the era of minimally invasive parathyroidectomy. *Journal of the American College of Surgeons*, **2010**, 210, 456-62	4.4	13
35	Maximum-relevance weighted likelihood estimator: application to the continual reassessment method. *Statistics and Its Interface*, **2010**, 3, 177-183	0.4	2
34	Autologous hematopoietic stem cell transplant in systemic sclerosis: quantitative high resolution computed tomography of the chest scoring. *Journal of Rheumatology*, **2009**, 36, 1460-3	4.1	27
33	Re: Dose escalation methods in phase I cancer clinical trials. *Journal of the National Cancer Institute*, **2009**, 101, 1732-3; author reply 1733-5	9.7	6
32	Hematopoietic progenitor cell mobilization and harvesting in children with malignancies: do the advantages of pegfilgrastim really translate into clinical benefit?. *Bone Marrow Transplantation*, **2009**, 43, 919-25	4.4	9

31	Sensitivity of dose-finding studies to observation errors. *Contemporary Clinical Trials*, **2009**, 30, 523-30	2.3	11
30	A survey of the way pharmacokinetics are reported in published phase I clinical trials, with an emphasis on oncology. *Clinical Pharmacokinetics*, **2009**, 48, 387-95	6.2	7
29	Interest in an original methodology to define the optimal dosage of interferon-alpha-2a in metastatic melanoma patients. *Melanoma Research*, **2009**, 19, 379-84	3.3	1
28	Bayesian design and conduct of phase II single-arm clinical trials with binary outcomes: a tutorial. *Contemporary Clinical Trials*, **2008**, 29, 608-16	2.3	33
27	Dose Estimation. *Pharmaceutical Medicine*, **2008**, 22, 35-40	2.3	
26	Long-term follow-up results after autologous haematopoietic stem cell transplantation for severe systemic sclerosis. *Annals of the Rheumatic Diseases*, **2008**, 67, 98-104	2.4	116
25	Quality assessment of phase I dose-finding cancer trials: proposal of a checklist. *Clinical Trials*, **2008**, 5, 478-85	2.2	15
24	Adaptive designs for dose-finding in non-cancer phase II trials: influence of early unexpected outcomes. *Clinical Trials*, **2008**, 5, 595-606	2.2	14
23	Identifying the Most Successful Dose (MSD) in Dose-Finding Studies **2008**, 1		
22	Evaluation of an algorithm based on peripheral blood hematopoietic progenitor cell and CD34+ cell concentrations to optimize peripheral blood progenitor cell collection by apheresis. *Transfusion*, **2007**, 47, 1851-7	2.9	27
21	Recent developments in adaptive designs for Phase I/II dose-finding studies. *Journal of Biopharmaceutical Statistics*, **2007**, 17, 1071-83	1.3	35
20	Phase I/II Clinical Trials **2007**, 1		
19	Colopharyngoplasty for the treatment of severe pharyngoesophageal caustic injuries: an audit of 58 patients. *Annals of Surgery*, **2007**, 246, 721-7	7.8	29
18	Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma. *Neuro-Oncology*, **2006**, 8, 60-6	1	159
17	Experimental designs for phase I and phase I/II dose-finding studies. *British Journal of Cancer*, **2006**, 94, 609-13	8.7	53
16	A phase I dose-finding and pharmacokinetic study of subcutaneous semisynthetic homoharringtonine (ssHHT) in patients with advanced acute myeloid leukaemia. *British Journal of Cancer*, **2006**, 95, 253-9	8.7	52
15	The Continual Reassessment Method **2006**, 131-148		0
14	Defining Stopping Rules **2006**, 205-224		

13	Websites and Software **2006**, 287-306		
12	Optimal designs for estimating the most successful dose. *Statistics in Medicine*, **2006**, 25, 4311-20	2.3	25
11	Identifying the most successful dose (MSD) in dose-finding studies in cancer. *Pharmaceutical Statistics*, **2006**, 5, 187-99	1	19
10	The VAD chemotherapy regimen plus a G-CSF dose of 10 microg/kg is as effective and less toxic than high-dose cyclophosphamide plus a G-CSF dose of 5 microg/kg for progenitor cell mobilization: results from a monocentric study of 82 patients. *Bone Marrow Transplantation*, **2006**,	4.4	18
9	A double-blind low dose-finding phase II study of granulocyte colony-stimulating factor combined with chemotherapy for stem cell mobilization in patients with non-Hodgkin's lymphoma. *Haematologica*, **2006**, 91, 550-3	6.6	9
8	Dose-finding study of ibuprofen in patent ductus arteriosus using the continual reassessment method. *Journal of Clinical Pharmacy and Therapeutics*, **2005**, 30, 121-32	2.2	96
7	Minimum effective dose of midazolam for sedation of mechanically ventilated neonates. *Journal of Clinical Pharmacy and Therapeutics*, **2005**, 30, 479-85	2.2	21
6	Identifying the Most Successful Dose (MSD) in Dose-Finding Studies **2005**, 1-5		
5	Software to compute and conduct sequential Bayesian phase I or II dose-ranging clinical trials with stopping rules. *Computer Methods and Programs in Biomedicine*, **2003**, 72, 117-25	6.9	30
4	Phase I (or phase II) dose-ranging clinical trials: proposal of a two-stage Bayesian design. *Journal of Biopharmaceutical Statistics*, **2003**, 13, 87-101	1.3	10
3	Autologous bone marrow transplantation in the treatment of refractory systemic sclerosis: early results from a French multicentre phase I-II study. *British Journal of Haematology*, **2002**, 119, 726-39	4.5	91
2	Alternate designs for conduct and analysis of phase I cancer trials. *Blood*, **2001**, 98, 1275-6	2.2	4
1	The continual reassessment method: comparison of Bayesian stopping rules for dose-ranging studies. *Statistics in Medicine*, **2001**, 20, 2827-43	2.3	85